


# Broken Antibiotics Market Puts Cancer Treatments at Risk

Despite antibiotics' vital role in cancer care, companies have abandoned their development in favor of more profitable drugs

**Antibiotics protect cancer patients from life-threatening complications and save lives.**

Severe infection and sepsis (a life-threatening related complication) are among the most common reasons that cancer patients are admitted to intensive care units.

Approximately **1 in 10** cancer deaths is due to severe sepsis—not the cancer itself.



**95%**

of oncologists surveyed worry about the impact of drug-resistant bacteria, or superbugs, on their patients.


**But the antibiotics market is broken.**

From 2014 to 2016, drug companies had more than...





**Most major drugmakers have exited the market, and smaller ones have gone bankrupt.**

From 2014 to 2020, the number of large pharmaceutical companies with new antibiotics in clinical development has fallen from **eight** to **two**, even as the need for effective antibiotics remains urgent.



**Drugmakers and private investors are abandoning antibiotic research and development because they lose money on antibiotics.**

**In 2019, private investment poured...**



**Urgent action would fix the broken antibiotics market and drive innovation of new antibiotics to protect cancer patients and save lives.**

Economic incentives are needed to jump-start the failing antibiotics market.

The federal government must create financial incentives to help drug companies recoup the costs of bringing critical new antibiotics to market.

Sources: ReAct, "Successful Cancer Treatment Relies On Effective Antibiotics" (2020); Longitude Prize, "Effectiveness of Cancer Treatments Threatened by Rising Antibiotic Resistance" (2020); Wellcome Trust, "It's Time to Fix the Antibiotic Market"; The Pew Charitable Trusts, "Tracking the Global Pipeline of Antibiotics in Development, April 2020"; A. Engel, "Economic Status Check" (presentation, 4th AMR Conference, pre-conference webinar, Aug. 8, 2020)